Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS

Melissa E Badowski,1 Sarah E Perez2 1Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA; 2Infectious Diseases Clinic, Tufts Medical Center, Boston, MA, USA Abstract: Since the beginning of the HIV...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Badowski ME, Perez SE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Dronabinol weight loss HIV/AIDS HIV wasting syndrome cachexia Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/76082a451fcb4810813a97a3381bda64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76082a451fcb4810813a97a3381bda64
record_format	dspace
spelling	oai:doaj.org-article:76082a451fcb4810813a97a3381bda642021-12-02T04:01:52ZClinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS1179-1373https://doaj.org/article/76082a451fcb4810813a97a3381bda642016-02-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-dronabinol-in-the-treatment-of-weight-loss-associa-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Melissa E Badowski,1 Sarah E Perez2 1Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA; 2Infectious Diseases Clinic, Tufts Medical Center, Boston, MA, USA Abstract: Since the beginning of the HIV/AIDS epidemic, weight loss has been a common complaint for patients. The use of various definitions defining HIV wasting syndrome has made it difficult to determine its actual prevalence. Despite the use of highly active antiretroviral therapy, it is estimated that the prevalence of HIV wasting syndrome is between 14% and 38%. HIV wasting syndrome may stem from conditions affecting chewing, swallowing, or gastrointestinal motility, neurologic disease affecting food intake or the perception of hunger or ability to eat, psychiatric illness, food insecurity generated from psychosocial or economic concerns, or anorexia due to medications, malabsorption, infections, or tumors. Treatment of HIV wasting syndrome may be managed with appetite stimulants (megestrol acetate or dronabinol), anabolic agents (testosterone, testosterone analogs, or recombinant human growth hormone), or, rarely, cytokine production modulators (thalidomide). The goal of this review is to provide an in-depth evaluation based on existing clinical trials on the clinical utility of dronabinol in the treatment of weight loss associated with HIV/AIDS. Although total body weight gain varies with dronabinol use (–2.0 to 3.2 kg), dronabinol is a well-tolerated option to promote appetite stimulation. Further studies are needed with standardized definitions of HIV-associated weight loss and clinical outcomes, robust sample sizes, safety and efficacy data on chronic use of dronabinol beyond 52 weeks, and associated virologic and immunologic outcomes. Keywords: dronabinol, weight loss, HIV/AIDS, HIV wasting syndrome, cachexiaBadowski MEPerez SEDove Medical PressarticleDronabinolweight lossHIV/AIDSHIV wasting syndromecachexiaImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2016, Iss Issue 1, Pp 37-45 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dronabinol weight loss HIV/AIDS HIV wasting syndrome cachexia Immunologic diseases. Allergy RC581-607
spellingShingle	Dronabinol weight loss HIV/AIDS HIV wasting syndrome cachexia Immunologic diseases. Allergy RC581-607 Badowski ME Perez SE Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
description	Melissa E Badowski,1 Sarah E Perez2 1Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA; 2Infectious Diseases Clinic, Tufts Medical Center, Boston, MA, USA Abstract: Since the beginning of the HIV/AIDS epidemic, weight loss has been a common complaint for patients. The use of various definitions defining HIV wasting syndrome has made it difficult to determine its actual prevalence. Despite the use of highly active antiretroviral therapy, it is estimated that the prevalence of HIV wasting syndrome is between 14% and 38%. HIV wasting syndrome may stem from conditions affecting chewing, swallowing, or gastrointestinal motility, neurologic disease affecting food intake or the perception of hunger or ability to eat, psychiatric illness, food insecurity generated from psychosocial or economic concerns, or anorexia due to medications, malabsorption, infections, or tumors. Treatment of HIV wasting syndrome may be managed with appetite stimulants (megestrol acetate or dronabinol), anabolic agents (testosterone, testosterone analogs, or recombinant human growth hormone), or, rarely, cytokine production modulators (thalidomide). The goal of this review is to provide an in-depth evaluation based on existing clinical trials on the clinical utility of dronabinol in the treatment of weight loss associated with HIV/AIDS. Although total body weight gain varies with dronabinol use (–2.0 to 3.2 kg), dronabinol is a well-tolerated option to promote appetite stimulation. Further studies are needed with standardized definitions of HIV-associated weight loss and clinical outcomes, robust sample sizes, safety and efficacy data on chronic use of dronabinol beyond 52 weeks, and associated virologic and immunologic outcomes. Keywords: dronabinol, weight loss, HIV/AIDS, HIV wasting syndrome, cachexia
format	article
author	Badowski ME Perez SE
author_facet	Badowski ME Perez SE
author_sort	Badowski ME
title	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
title_short	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
title_full	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
title_fullStr	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
title_full_unstemmed	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
title_sort	clinical utility of dronabinol in the treatment of weight loss associated with hiv and aids
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/76082a451fcb4810813a97a3381bda64
work_keys_str_mv	AT badowskime clinicalutilityofdronabinolinthetreatmentofweightlossassociatedwithhivandaids AT perezse clinicalutilityofdronabinolinthetreatmentofweightlossassociatedwithhivandaids
_version_	1718401497036750848

Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS

Ejemplares similares